Perigon Wealth Management’s NovoCure NVCR Stock Holding History

Perigon Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-265	Closed	-$46K	–	851
2020 Q4	$46K	Buy	+265	New	+$36.3K	0.01%	767

Other funds holding NVCR

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perigon Wealth Management's NVCR Position: Q1 2021 in Review

Perigon Wealth Management sold out of NovoCure (NVCR) in Q1 2021, closing a stake of 265 shares — an estimated $46K sold.

Perigon Wealth Management first reported a position in NVCR in Q4 2020 and held it in 1 quarter. The position peaked at $46K in Q4 2020. 327 funds tracked by Wall St. Rank hold NVCR as of Q1 2021.

Perigon Wealth Management reported no remaining NovoCure position as of Q1 2021 after selling out during the quarter.
Perigon Wealth Management sold 265 NovoCure shares in Q1 2021, an estimated $46K.
Perigon Wealth Management first reported a position in NovoCure in Q4 2020 and held it in 1 quarter.
Perigon Wealth Management's NovoCure position peaked at $46K in Q4 2020.
327 funds tracked by Wall St. Rank held NovoCure as of Q1 2021.

Based on Perigon Wealth Management's 13F filing for Q1 2021, filed 17 May 2021.